ClinicalTrials.gg
Not yet recruitingNCT07855146AVAPAMUpdated Oct 2, 2026

Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique

An interventional study of The patient will be offered the various possible methods of inducing cervical ripening, and the choice of method will be left to her and Standard Care (in control arm) in Pregnancy, Cervical Ripening and Childbirth, sponsored by Centre Hospitalier Régional Metz-Thionville. Not yet recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Centre Hospitalier Régional Metz-Thionville · Not applicable, Interventional, and Treatment

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, single-centre, quasi-experimental before-and-after study. Women due to give birth at the participating centre will be informed about the study during their 9th-month antenatal appointment. Only expectant mothers for whom cervical ripening is indicated will be included. During the BEFORE period, cervical ripening will be offered to them according to the method chosen by the healthcare team following a discussion of their case at a team meeting. During the AFTER period, the various possible methods of cervical ripening will be offered to the patient, and the choice of method will be left to her.

The participants' experiences will be compared using the QEVA self-assessment questionnaire, completed two days after delivery.

Read the detailed description

Induction of labour is a common practice in France, and the rate is rising. Cervical ripening and induction of labour are often associated with negative maternal experiences of labour and childbirth. The experience of childbirth has a significant influence on the early mother-child relationship, as well as on the relationship between the parents. A negative experience of childbirth is a major risk factor for postnatal depression and post-traumatic stress disorder.

02

Conditions studied

  • Pregnancy
  • Cervical Ripening
  • Childbirth

Keywords

  • Overall experience of childbirth
03

In context

Lead sponsor

Centre Hospitalier Régional Metz-Thionville is the lead sponsor of 123 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged over 18
  • Patients who gave their written consent after receiving information to enable them to make an informed decision about the study
  • Patients with a medical or non-medical indication for induction of labour who are admitted to the maternity ward of the participating centre

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of uterine scarring (a history of uterine scarring is a to prostaglandins)
  • Patients requiring urgent maturation
  • Patients requiring induction of labour in connection with a medical termination of pregnancy or foetal death in utero
  • Patients who are unable to complete the questionnaire (due to a lack of proficiency in the language, cognitive impairments, etc.)
  • Women deprived of their liberty and/or protected by law
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Other
    Period before

    Other: Standard Care (in control arm)

  • Experimental
    Period after

    Other: The patient will be offered the various possible methods of inducing cervical ripening, and the choice of method will be left to her

Interventions

  • OtherThe patient will be offered the various possible methods of inducing cervical ripening, and the choice of method will be left to her

    Choice of cervical ripening technique from the following: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta®, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon).

  • OtherStandard Care (in control arm)

    Cervical ripening will be offered to them in accordance with the approach chosen by the healthcare team following a discussion of her case at a team meeting.

06

What researchers measure

Primary outcomes

  1. Score of the first dimension of the QEVA questionnaire

    Total score of the dimension: 'emotions during childbirth' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Evaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome.

    Time frame: 2 days after giving birth

Secondary outcomes

  1. Score of the second dimension of the QEVA questionnaire

    Total score of the dimension 'interactions with healthcare professionals' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome.

    Time frame: 2 days after giving birth

  2. Score of the third dimension of the QEVA questionnaire

    Total score of the dimension 'first moments with the baby' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 3 to 12, a higher score means a worse outcome.

    Time frame: 2 days after giving birth

  3. Score of the fourth dimension of the QEVA questionnaire

    Total score of the dimension : 'feeling during the postpartum period' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 4 to 16, a higher score means a worse outcome.

    Time frame: 2 days after giving birth

  4. Procedures for informing patients about their experience of childbirth

    Multiple choice: 1/information provided by a healthcare professional during a consultation (the patient's referring obstetrician or midwife), 2/our hospital's patient information leaflet, 3/antenatal classes, and 4/other sources (social media, etc.), expressed as percentages of the total number of participants.

    Time frame: 2 days after giving birth

  5. Impact of the duration of antenatal care on the experience of childbirth

    Assessment of the duration of care from the start of maturation to birth (days)

    Time frame: At baseline

  6. Impact of the maturation technique used on the experience of childbirth

    Assessment of the impact of the ripening technique used on the childbirth experience for the following techniques: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon)

    Time frame: At baseline

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 2, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07855146
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Mélanie JUNKE
Contact
projet-recherche-clinique@chr-metz-thionville.fr
0033387179886
Cristina-Elena DOROFTE, MD
principal investigator · CHR Metz Thionville Hopital Femme Mère Enfant

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion